Need a report that reflects how COVID-19 has impacted this market and its growth?
The Chinese diabetes care devices market is expected to register a CAGR greater than 6% during the forecast period (2021 - 2026). China is anticipated to dominate the market in Asia-Pacific, during the forecast period, owing to the rising prevalence of diabetes in the region. There have been significant developments in insulin delivery systems technology, ranging from insulin injections to insulin pumps. Technological innovations and advancements offer many conveniences in measuring blood glucose levels. One such advancement in monitoring blood glucose levels was the introduction of continuous glucose monitoring devices.
Scope of the Report
The study provides a detailed analysis of the diabetes care devices market in China and includes market share, size, forecast, and industry overview.
Key Market Trends
Increase in Diabetes Population
China stands third in number among the countries, with the highest diabetes population. The incidence of Type 2 diabetes (T2D) has rapidly increased over the past decade, and it has become a leading public health challenge in China. The growth in the Chinese diabetic market is driven by increasing diabetes patients, growth in high-calorie diets, and sedentary lifestyles. This has led the country to record the highest number of diabetes patients in the world, totaling 126 million people in 2020, roughly 8% of the population. About 126 million people were suffering from diabetes mellitus in 2020, with a prevalence of 10.9% among adults. Out of the 126 million diabetic patients, 12.49 million were Type 1 patients and 114.2 million were Type 2 patients.
To understand key trends, Download Sample Report
Self-monitoring Blood Glucose Devices Recorded the Highest Market Share in the Chinese Diabetes Devices Market in 2019
The Chinese self-monitoring blood glucose (SMBG) devices market was valued at 0.97 USD billion in 2020, and it is expected to reach USD 1.4 billion by 2026. It is also likely to witness a CAGR of above 6.5% during the forecast period (2021 - 2026). In the SBGM market, the glucometer test strips and lancets together account for 86.9% of the share, while the glucometer devices account for 13% of the share. The CAGR of glucometer devices is high, as compared to glucometer test strips and glucometer lancets, and it is estimated to be 8.3% during the forecast period. The prevalence of diabetes in the country is rising steadily, and, as of now, nearly 9% of the total adult population has diabetes. However, the lack of awareness about the benefits of monitoring blood glucose levels, low access to healthcare services, and little health awareness, especially among the diabetes population in some parts of China, are the main reasons that are hindering the growth of the blood glucose monitoring market in the country.
Constant innovations are made by manufacturers to compete and struggle in the market. The major players, such as Abbott and Medtronic, resort to inorganic market strategies, such as mergers and acquisitions, to establish market dominance, while also adhering to organic growth strategies, which are evident from the R&D spending of these companies.
In May 2021, Chinese medical device innovation hub Dinova Medtech and US-based medical device company Metronom Health have established a joint venture to develop and sell a continuous glucose monitoring system in China.
Table of Contents
1.1 Study Assumptions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.3 Industry Attractiveness - Porter's Five Forces Analysis
4.3.1 Bargaining Power of Suppliers
4.3.2 Bargaining Power of Consumers
4.3.3 Threat of New Entrants
4.3.4 Threat of Substitute Products and Services
4.3.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Device
5.1.1 By Monitoring Devices, (Value and Volume, 2016 - 2026)
188.8.131.52 Self-monitoring Blood Glucose Devices
184.108.40.206.1 Glucometer Devices
220.127.116.11.2 Test Strips
18.104.22.168 Continuous Glucose Monitoring
22.214.171.124.2 Receivers (Receivers and Transmitters)
5.1.2 By Management Devices, (Value and Volume, 2016 - 2026)
126.96.36.199 Insulin Delivery Devices
188.8.131.52.1 Insulin Pump
184.108.40.206.1.1 Insulin Pump Device
220.127.116.11.1.2 Insulin Pump Reservoir
18.104.22.168.1.3 Infusion Set
22.214.171.124.2 Insulin Syringes
126.96.36.199.3 Insulin Disposable Pens
188.8.131.52.4 Insulin Cartridges in Reusable pens
184.108.40.206.5 Insulin Jet Injectors
6. MARKET INDICATORS
6.1 Type 1 Diabetes Population (2016 - 2026)
6.2 Type 2 Diabetes Population (2016 - 2026)
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.3 Johnson & Johnson
7.1.4 Novo Nordisk
7.1.5 Becton, Dickinson & Company
7.1.9 ARKRAY Inc.
7.1.10 Ascensia Diabetes Care
7.1.11 ACON Laboratories Inc.
7.1.12 Eli Lilly
7.1.13 Bionime Corporation
7.1.14 Rossmax International Ltd
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The China Diabetes Devices Market market is studied from 2016 - 2026.
What is the growth rate of China Diabetes Devices Market?
The China Diabetes Devices Market is growing at a CAGR of >5% over the next 5 years.
What is China Diabetes Devices Market size in 2016?
The China Diabetes Devices Market is valued at 6 Billion USD in 2016.
What is China Diabetes Devices Market size in 2026?
The China Diabetes Devices Market is valued at 8 Billion USD in 2026.
Who are the key players in China Diabetes Devices Market?
Abbott, Medtronics, Roche, Becton, Dickinson & Company, Dexcom are the major companies operating in China Diabetes Devices Market.